Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF +2.72%49 Days Sales Outstanding is 69.19 as of Dec. 2025, which is 48% above its 10-year median of 46.90. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Abingdon Health ranks better than 55.94% on this metric.
The historical rank and industry rank for Abingdon Health's Days Sales Outstanding or its related term are showing as below:
ABDXF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.66 Med: 46.9 Max: 1050.65
Current: 62.8
During the past 8 years, Abingdon Health's highest Days Sales Outstanding was 1050.65. The lowest was 22.66. And the median was 46.90.
ABDXF's Days Sales Outstanding is ranked better than 55.94% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.855
vs ABDXF: 62.80
Abingdon Health's Days Sales Outstanding
declined
from Dec. 2024 (78.70) to Dec. 2025 (69.19).
Abingdon Health (OTCPK:ABDXF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Abingdon Health Days Sales Outstanding Related Terms
Abingdon Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Days Sales Outstanding falls into.
Abingdon Health Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Days Sales Outstanding of 69.19 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Abingdon Health and its competitors. This is 48% above median its historical median of 46.90. Over the past decade, Abingdon Health's Days Sales Outstanding has ranged from 22.66 to 1,050.65. According to the industry distribution chart, Abingdon Health ranks #89 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 44.1%.
Is Abingdon Health's Days Sales Outstanding too high?
Abingdon Health's current Days Sales Outstanding of 69.19 is 48% above median its 10-year median of 46.90. Over the past 10 years, this metric has ranged from a low of 22.66 to a high of 1,050.65. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.86. Abingdon Health's value of 69.19 is 2% above this industry median. Based on the distribution chart, Abingdon Health ranks #89 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #89 out of 202 companies for Days Sales Outstanding. This puts Abingdon Health in the upper half of its industry. The industry median Days Sales Outstanding is 67.86. Abingdon Health's value of 69.19 is 2% above this benchmark. Historically, Abingdon Health's own Days Sales Outstanding has ranged from 22.66 to 1,050.65 over the past decade. While the company's 10-year median is 46.90 vs. the industry median of 67.86, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Days Sales Outstanding of 69.19 is 2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Days Sales Outstanding is 69.19, which is 48% above median its own 10-year median of 46.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 29.8% below its estimated fair value. The current Days Sales Outstanding is 69.19, which is 48% above median its 10-year median of 46.90 and 2% above the Medical Diagnostics & Research industry median of 67.86. Abingdon Health's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Days Sales Outstanding is 69.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.15 is trading 29.8% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
Days Sales Outstanding: 69.19 (48% above median its 10-year median of 46.90)
GF Value™: $0.21 vs. price of $0.15 (29.8% below fair value)
Industry Position: 2% above the Medical Diagnostics & Research median (#89 of 202)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
